Literature DB >> 6313776

Eccrine spiradenoma: clinical and pathologic study of 49 tumors.

N C Mambo.   

Abstract

A clinical and pathologic study of 49 eccrine spiradenomas occurring in 46 patients is presented. The study showed that pain and/or tenderness are not such characteristic clinical features of this tumor as has previously been suggested; either or both were present in only 23% of the 35 patients with well-documented clinical histories. Some pathologic features, not previously documented in this tumor, were seen and included: cylindromatous foci, aggregates of stromal clear cells, clear cells lining ducts and ulceration of the overlying epidermis. Two tumors had undergone malignant transformation, but there were no recurrences in the 35 patients with adequate follow-up.

Entities:  

Mesh:

Year:  1983        PMID: 6313776     DOI: 10.1111/j.1600-0560.1983.tb00333.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  5 in total

1.  Multiple Segmental Eccrine Spiradenoma with a Zosteriform Pattern: A Case Report and Literature Review.

Authors:  Fang Ren; Zhili Hu; Qingtao Kong; Hong Sang
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

2.  Benign eccrine spiradenoma imitating a nerve sheath tumor: illustrative case.

Authors:  Kelsey M Bowman; Daniel D Bennett; Amgad S Hanna
Journal:  J Neurosurg Case Lessons       Date:  2022-06-20

3.  A serpentine inside eccrine spiradenoma: a new trichoscopic sign.

Authors:  Balachandra S Ankad; Savitha L Beergouder; Vijay Domble; L Sujana
Journal:  Int J Trichology       Date:  2015 Jan-Mar

4.  Eccrine Spiradenoma of the Scalp.

Authors:  Jaehee Kim; Ho Jik Yang; Jung-Soo Pyo
Journal:  Arch Craniofac Surg       Date:  2017-09-26

Review 5.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.